After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

The CDC Foundation has added muscle to its “Live to the Beat” campaign, enlisting former NFL star Jerome “The Bus” Bettis to ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Avalere Health has reset both its executive team and mission. | Amar Urhekar has reset Avalere Health’s mission. Weeks after naming Urhekar as CEO, the biopharma commercialization partner has aligned ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...